"What" Series

What are adverse events?

13 January 2024
2 min read

Adverse event (AE) refers to any adverse event that may occur to the subject in the clinical trial and may be related to the trial treatment and trial treatment.

Medical events related or not necessarily related to the tested drugs. Therefore, an adverse event can be any adverse or unexpected signs (including abnormal laboratory test results), symptoms or a kind of signs that may or may not be related to the test drug-a temporary disease that may be related to the use of drugs. The recording of adverse events is an important means to evaluate the safety of drugs used in trials. Therefore, at each follow-up visit, the investigator should ask the subject about any adverse events in detail. Although some adverse events were spontaneously reported by the subjects to the researchers, most trials still required the researchers to collect the occurrence of adverse events from the subjects through non inductive questions, such as "is there any discomfort after taking medicine?". In case of any adverse event, including the known adverse reaction of the trial drug, whether related to the trial drug or not, the investigator shall record it in detail in the case report form according to the requirements of the trial protocol.

UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
Latest Hotspot
3 min read
UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
13 January 2024
UCB has revealed that the European Commission has sanctioned the use of RYSTIGGO (rozanolixizumab) for treating generalized myasthenia gravis in adult patients across Europe.
Read →
Exploring the Latest AGT siRNA Deal by Sanegene Bio (Suzhou): A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest AGT siRNA Deal by Sanegene Bio (Suzhou): A Guide to Rapidly Accessing Transaction Insights
13 January 2024
Innovent Biologics and Sanegene Bio (Suzhou) announced their partnership to co-develop SGB-3908, an siRNA drug targeting AGT for hypertension treatment.
Read →
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
Latest Hotspot
3 min read
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
13 January 2024
OBI Pharma has disclosed that the FDA has given its approval for a Phase 1/2 clinical trial application concerning OBI-992, a TROP2 antibody-drug conjugate.
Read →
Why is it sometimes difficult to enroll subjects?
Knowledge Base
4 min read
Why is it sometimes difficult to enroll subjects?
13 January 2024
The trial protocol should strictly define what subjects can be enrolled (enrollment criteria) and what subjects cannot be enrolled (exclusion criteria).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.